180 related articles for article (PubMed ID: 15517484)
1. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease.
Brauckhoff M; Gimm O; Weiss CL; Ukkat J; Sekulla C; Brauckhoff K; Thanh PN; Dralle H
World J Surg; 2004 Dec; 28(12):1305-11. PubMed ID: 15517484
[TBL] [Abstract][Full Text] [Related]
2. Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective.
Brauckhoff M; Machens A; Lorenz K; Bjøro T; Varhaug JE; Dralle H
Ann Surg; 2014 Apr; 259(4):800-6. PubMed ID: 23979292
[TBL] [Abstract][Full Text] [Related]
3. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.
Jasim S; Ying AK; Waguespack SG; Rich TA; Grubbs EG; Jimenez C; Hu MI; Cote G; Habra MA
Thyroid; 2011 Feb; 21(2):189-92. PubMed ID: 21186952
[TBL] [Abstract][Full Text] [Related]
4. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation.
Gimm O; Marsh DJ; Andrew SD; Frilling A; Dahia PL; Mulligan LM; Zajac JD; Robinson BG; Eng C
J Clin Endocrinol Metab; 1997 Nov; 82(11):3902-4. PubMed ID: 9360560
[TBL] [Abstract][Full Text] [Related]
5. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
6. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
[TBL] [Abstract][Full Text] [Related]
7. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
[TBL] [Abstract][Full Text] [Related]
9. Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese.
Zhang ZW; Guo X; Qi XP
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):534-543. PubMed ID: 32914730
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and genetic profile of patients with medullary thyroid cancer treated in the Cancer Centre--Institute of Oncology in Warsaw].
Czetwertyńska M; Kozłowicz-Gudzińska I; Stachlewska-Nasfeter E; Sromek M; Skasko E; Paszko Z
Endokrynol Pol; 2006; 57(4):415-9. PubMed ID: 17006846
[TBL] [Abstract][Full Text] [Related]
11. The Reality of Multiple Endocrine Neoplasia Type 2B Diagnosis: Awareness of Unique Physical Appearance Is Important.
Nagaoka R; Sugitani I; Sanada M; Jikuzono T; Okamura R; Igarashi T; Akasu H; Shimizu K
J Nippon Med Sch; 2018; 85(3):178-182. PubMed ID: 30135345
[TBL] [Abstract][Full Text] [Related]
12. Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: An exploratory analysis.
Brauckhoff M; Machens A; Hess S; Lorenz K; Gimm O; Brauckhoff K; Sekulla C; Dralle H
Surgery; 2008 Dec; 144(6):1044-50; discussion 1050-3. PubMed ID: 19041016
[TBL] [Abstract][Full Text] [Related]
13. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
Mathiesen JS; Habra MA; Bassett JHD; Choudhury SM; Balasubramanian SP; Howlett TA; Robinson BG; Gimenez-Roqueplo AP; Castinetti F; Vestergaard P; Frank-Raue K
J Clin Endocrinol Metab; 2017 Jun; 102(6):2069-2074. PubMed ID: 28323957
[TBL] [Abstract][Full Text] [Related]
14. [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].
Frank-Raue K; Heimbach C; Rondot S; Usadel KH; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
Dtsch Med Wochenschr; 2003 Sep; 128(39):1998-2002. PubMed ID: 14508694
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B.
O'Riordain DS; O'Brien T; Weaver AL; Gharib H; Hay ID; Grant CS; van Heerden JA
Surgery; 1994 Dec; 116(6):1017-23. PubMed ID: 7985081
[TBL] [Abstract][Full Text] [Related]
16. Germline mutation of RET codon 883 in two cases of de novo MEN 2B.
Smith DP; Houghton C; Ponder BA
Oncogene; 1997 Sep; 15(10):1213-7. PubMed ID: 9294615
[TBL] [Abstract][Full Text] [Related]
17. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
18. Multiple endocrine neoplasia type 2B--genetic basis and clinical expression.
Lee NC; Norton JA
Surg Oncol; 2000 Nov; 9(3):111-8. PubMed ID: 11356339
[TBL] [Abstract][Full Text] [Related]
19. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
20. Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma.
Dourisboure RJ; Belli S; Domenichini E; Podestá EJ; Eng C; Solano AR
Thyroid; 2005 Jul; 15(7):668-71. PubMed ID: 16053382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
